KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) EBIT (2016 - 2025)

Inovio Pharmaceuticals' EBIT history spans 16 years, with the latest figure at -$21.2 million for Q3 2025.

  • For Q3 2025, EBIT rose 22.44% year-over-year to -$21.2 million; the TTM value through Sep 2025 reached -$89.7 million, up 24.88%, while the annual FY2024 figure was -$112.4 million, 21.91% up from the prior year.
  • EBIT for Q3 2025 was -$21.2 million at Inovio Pharmaceuticals, up from -$23.1 million in the prior quarter.
  • Across five years, EBIT topped out at -$20.4 million in Q4 2024 and bottomed at -$105.5 million in Q4 2021.
  • The 5-year median for EBIT is -$35.8 million (2022), against an average of -$47.1 million.
  • The largest annual shift saw EBIT tumbled 259.61% in 2021 before it skyrocketed 64.43% in 2023.
  • A 5-year view of EBIT shows it stood at -$105.5 million in 2021, then soared by 46.97% to -$55.9 million in 2022, then soared by 51.04% to -$27.4 million in 2023, then grew by 25.64% to -$20.4 million in 2024, then fell by 4.13% to -$21.2 million in 2025.
  • Per Business Quant, the three most recent readings for INO's EBIT are -$21.2 million (Q3 2025), -$23.1 million (Q2 2025), and -$25.1 million (Q1 2025).